Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

15.53
+0.07000.45%
Post-market: 15.52-0.0100-0.06%19:30 EDT
Volume:567.53K
Turnover:8.84M
Market Cap:999.43M
PE:-4.48
High:15.95
Open:15.41
Low:15.24
Close:15.46
52wk High:23.19
52wk Low:6.73
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.46
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:3.11
PE(LYR):-4.17

Loading ...

Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM) and Pfizer (PFE)

TIPRANKS
·
Jun 08

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) and Cullinan Management (CGEM)

TIPRANKS
·
Jun 08

Cullinan Therapeutics presents clinical data for CLN-978

TIPRANKS
·
Jun 08

Cullinan Therapeutics Inc -Cln-978 Shows Favorable Safety Profile With Single Target Doses up to 30 ΜG as Well as Initial Multi-Dose Regimen

THOMSON REUTERS
·
Jun 06

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

GlobeNewswire
·
Jun 06

Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors

TIPRANKS
·
Jun 06

Cullinan Therapeutics to present initial multi-dose clinical data for CLN-978 in rheumatoid arthritis study

Reuters
·
May 26

Stifel Nicolaus Reaffirms Their Buy Rating on Cullinan Management (CGEM)

TIPRANKS
·
May 25

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM)

TIPRANKS
·
May 20

Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street

TIPRANKS
·
May 20

Cullinan Therapeutics wins FDA orphan drug designation for CLN-049 in relapsed AML

Reuters
·
May 19

Cullinan Therapeutics Receives FDA Orphan Drug Designation for Cln-049, a Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

THOMSON REUTERS
·
May 19

Cullinan Therapeutics Price Target Maintained With a $38.00/Share by BTIG

Dow Jones
·
May 19

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Cullinan Management (CGEM)

TIPRANKS
·
May 19

Cullinan presents initial Phase 1 CLN-978 data in refractory RA, SLE at EULAR 2026

Reuters
·
May 19

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

GlobeNewswire
·
May 19

AnaptysBio names Christopher Murphy as CFO

Reuters
·
May 11

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 11

Cullinan Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
May 08

Cullinan Therapeutics price target raised to $37 from $36 at Wedbush

TIPRANKS
·
May 08